Clinical translation of angiogenesis inhibitors
By R. Kerbel, J. Folkman. Nature Reviews. Cancer, 2002
1,601 citations recorded by the source corpus.
Subfields: Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/1ccf896497d53f273d63b2a6a669e84bdb455d9f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Angiogenesis as a therapeutic target (2005, background): “These advances notwithstanding, much progress is needed on a variety of important issues; for example, how do we achieve the most effective combinations of antiangiogenic agents with chemotherapy or other biological agents and how do we select patients that are most likely to respond to the treatmen”
- The dawning era of polymer therapeutics (2003, background): “Although a large number of anti-angiogenic agents are already in clinical developmen”
- Cannabinoids: potential anticancer agents (2003, background): “To grow beyond minimal size, tumours must generate a new vascular supply (angiogenesis) for purposes of cell nutrition, gas exchange and waste disposal — therefore, blocking the angiogenic process constitutes one of the most promising antitumour approaches now availabl”
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. (2003, neutral): “Introduction Neovascularization is a common attribute of tumors, and a wealth of functional studies support the proposition that blood vessels are crucial for the formation, growth, and dissemination of cancer (1, 2).”
- The biology of VEGF and its receptors (2003, background): “Some evidence suggests that VEGF may be especially critical during the initial stage”
- Friends or foes — bipolar effects of the tumour stroma in cancer (2004, background): “Targeting the tumour vasculature has become an attractive possibility as a form of anticancer therap”
- Cancer genes and the pathways they control (2004, background): “First, naturally occurring inhibitors of angiogenesis were identified and shown to hinder the growth of experimental tumor”
- The multifaceted circulating endothelial cell in cancer: towards marker and target identification (2006, background): “Although the results of recent clinical trials indicate that some anti-angiogenic drugs might prolong the survival of patients, these problems necessitate the development of alternative pharmacodynamic surrogate markers and their validation at the preclinical and clinical leve”
- Engineering tumors with 3D scaffolds (2007, background): “Angiogenic capacity of engineered tumor microenvironments Tumor angiogenesis is regulated by an overbalance of pro-angiogenic factors, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and interleukin-8 (IL-8”